Melanoma & Skin Cancer | Specialty

Neoadjuvant Data Explored for Locally Advanced Melanoma

June 23rd 2020

pCR and Neoadjuvant Therapy for Melanoma

June 23rd 2020

Molecular Testing in Locally Advanced Melanoma

June 23rd 2020

Identifying Patients for Neoadjuvant Melanoma Therapy

June 23rd 2020

Optimal Management of Locally Advanced Melanoma

June 23rd 2020

Dr. Weber on Research Efforts Examining Neoadjuvant Approaches in Melanoma

June 23rd 2020

Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.

Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma

June 9th 2020

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Eggermont Elucidates Activity With Adjuvant Pembrolizumab in Resected Stage III Melanoma

June 8th 2020

Alexander Eggermont, MD, PhD, discusses the impact of the 3-year follow-up data from the phase 3 double-blind EORTC 1325/KEYNOTE-054 trial in high-risk stage III melanoma.

Research Efforts Abound in Rapidly Evolving BRAF-Mutant Melanoma Paradigm

June 8th 2020

Charles L. Sawyers, MD, provides additional insight into the IMspire150 and SWOG S1320 trials presented at the 2020 AACR Annual Virtual Meeting I and underscored the need for additional research in this space.

Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma

June 4th 2020

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.

Dabrafenib/Trametinib Demonstrates 5-Year RFS Benefit in BRAF+ Melanoma

June 4th 2020

Axel Hauschild, MD, PhD, discusses the 5-year findings from the COMBI-AD trial.

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC

May 31st 2020

In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

May 30th 2020

The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.

5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma

May 30th 2020

Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

May 13th 2020

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

May 13th 2020

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Algazi Attests to Benefit of Continuous Dosing of BRAF/MEK Inhibitors in Melanoma

May 6th 2020

Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.

Cemiplimab Shows Strong Activity in Pivotal Basal Cell Carcinoma Trial

May 5th 2020

Cemiplimab induced clinically meaningful and durable responses in patients with advanced basal cell carcinoma.

Neoadjuvant Nivolumab Shows Strong Clinical Activity in Merkel Cell Carcinoma

May 4th 2020

Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.